Introduction
Expression of the transcription factor forkhead box P3 (FOXP3) in T regulatory cells (Tregs) is necessary and sufficient for Tregs to suppress the effector function of conventional T (Tconv) cells. In cooperation with other transcription factors, including NFAT and Runx1, and the Th17-associated transcription factors ROR-γt and RORα, FOXP3 establishes the Treg program by repressing or trans-activating defined genes. 1, 2 The molecular mechanisms of FOXP3-mediated regulation of gene transcription are not clearly defined, but repression involves interactions with the histone acetyl-transferase TIP60, the histone deacetylase HDAC7, and linker histone H1.5. 3, 4 Following its discovery in Tregs, it was soon demonstrated that FOXP3 is also expressed transiently in human Tconv cells following TCR activation. [5] [6] [7] [8] [9] [10] [11] Similarly, another Tregassociated transcription factor, Helios, can also be expressed upon activation. 12 The major differences between FOXP3 in Tregs and Tconv cells are in stability and expression levels. In
Tregs, the Treg-specific de-methylated region (TSDR) region of the FOXP3 promoter is demethylated, permitting high and stable expression. 13 Conversely, in Tconv cells, the TSDR is methylated, resulting in transient expression of FOXP3 that never reaches the intensity of that in similarly activated Tregs. 6, 7, 9, 13 Transient FOXP3 expression in Tconv cells does not prevent cytokine production and or confer suppressive capacity, although this has been a point of controversy. [5] [6] [7] [8] [9] [10] [11] Another role for FOXP3 is to antagonize Th17 cell development. Interaction of FOXP3
with ROR-γt or Runx1 inhibits IL-17 production, 1 whereas ROR-γt together with hypoxiainducible factor 1α inhibits FOXP3. 14 cells and contributed to their phenotype by suppressing IFN-γ production and up-regulating expression of CCR4. These data reveal a novel function for FOXP3 and indicate that this transcription factor intrinsically regulates multiple T cell subsets.
Materials and methods

Isolation and cloning of human T cells. Peripheral blood was obtained from healthy volunteers
and a female carrier of a T to C mutation at the second coding nucleotide in FOXP3 18 on a BD FACS Aria (BD Biosciences, Mississauga, Ontario, Canada), and cloned as described.
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X-chromosome inactivation analysis was performed 18 to determine which allele of FOXP3 was active.
Microarray Analysis and validation. RNA was isolated from FOXP3 WT or null T cell clones, which were unstimulated (0h) or stimulated (72h) with immobilized anti-CD3 (10 μ g/ml) and soluble anti-CD28 mAbs (1 μ g/ml, BD Biosciences) at 10 6 cells/ml. Total RNA was hybridized to a GeneChip Human Gene 1.0 ST array (Affymetrix, Santa Clara, CA) according to the manufacturer's instructions. Hybridized arrays were washed and stained on a gene Chip Fluidics Station 450 and scanned on a Gene Chip Scanner 3000 7G (Affymetrix), generating an intensity file (*.CEL). CEL files were analyzed by RMA quantile normalization using the R package oligo. 22 Differential gene expression was assessed using linear models through the R package limma. 23 A cluster of HLA genes was removed due to their sequence similarity and thus difficulty in evaluating the significance of differential expression. Genes showing P values < 0.05 (Benjamini and Hochberg correction for multiple comparisons) were considered significant.
Bioinformatic analysis showed that the most statistically significant differences were attributable to FOXP3 genotype rather than activation state. Hence data from unstimulated and stimulated cells were combined and differential expression based on genotype was determined. The dataset is in the NCBI Gene Expression Omnibus, GSE41087.
To validate gene expression, expression of mRNAs was quantitatively assessed by real time PCR using KAPA SYBR green FAST qPCR Kit (KAPA biosystem) in a ViiA7 real time system (Applied Biosystem). Each sample was assayed in duplicate for at least three runs and results were normalized to β microglobulin and HPRT.
Pathway analysis. Gene Set Enrichment Analysis (GSEA) 24 was performed using RefSeq annotated genes that were differentially expressed between FOXP3 WT and null clones. The resulting pathways (C2) were filtered using an adjusted P-value < 0.05 (Benjamini and Hochberg correction, R function: p.adjust 25 ) and cross validated using randomized lists of background genes. Briefly, randomized lists of the same length as the differentially expressed list were obtained from the list of non-significantly changed genes between FOXP3 WT and null clones.
The lists were used as input for GSEA canonical pathways analysis and the pathways arising from those analyses were removed from the list of differentially expressed genes. Only those pathways with more than four genes in overlap are shown. 
Results
FOXP3 null human Tconv cell clones proliferate more and produce more IFN-γ and IL-2 than wild type Tconv clones.
FOXP3 is located on the X-chromosome and, in females, is subject to X-chromosome inactivation. 18 Tregs from carriers of FOXP3 mutations have a skewed pattern of X-inactivation with de-methylation of the wild-type allele, whereas Tconv cells have a random X-inactivation profile. 18 We sorted CD4 
Differential gene expression in FOXP3 null versus WT Tconv clones
To identify genes regulated by FOXP3 in Tconv cells, we performed microarray gene expression analysis in FOXP3 null and WT clones and found significant differences (Benjamini-Hochberg adjusted p-value < 0.05) in the expression of 274 genes (182 down-regulated and 92 up-regulated) that permitted hierarchical clustering on the basis of the FOXP3 genotype ( Figure 2A) . GSEA was applied and the results highlighted FOXP3-regulated expression of processes linked to immune cell biology, signaling and inflammatory response ( Figure 2B ). Eleven genes were selected to validate based on their fold change and biological relevance, and differential expression of 6 of these was confirmed ( Figure 2C ).
Notably, CORO1A and HNRPll belong to a previously reported list of FOXP3 targets 30 .
Knock-down of activation-induced FOXP3 expression in human Tconv cells with siRNA increases their proliferation.
To exclude the possibility that the effects of FOXP3 deficiency were restricted to carriers of FOXP3 mutations, we knocked-down expression of activation-induced FOXP3 by transducing naive Tconv cells from healthy donors with a lentiviral vector encoding a small interfering RNA against FOXP3 (siFOXP3). In Tregs, this vector decreases expression of FOXP3 by an average of 64%. 27 Purified transduced T cell lines were activated, and expression of siFOXP3 resulted in an average reduction in FOXP3 expression of 54.9 ± 3.29% ( Figure 3A and B) .
To determine whether siFOXP3-expressing T cells had changes in proliferation and/or cytokine production, siRNA-transduced Tconv cells were labeled with CFSE, and proliferation was measured 4 days after stimulation. As for FOXP3 null T cell clones, siFOXP3-transduced Tconv cells proliferated significantly more than control-transduced cells ( Figure 3C ). There was also a trend towards greater IFN-γ and IL-2 production by siFOXP3-expressing T cells ( Figure   3D ), but this result did not reach statistical significance.
In addition to repressing cytokines, FOXP3 positively regulates cell surface markers including CD25 and CTLA-4. 19, 31 These markers were analyzed after activation with varying strengths of stimulus, but no difference was found in expression of CTLA-4 or CD25 between control-or siFOXP3-transduced Tconv cells (data not shown). was measured after activation. In contrast to the chemokine receptor-sorted cells, and consistent with Nistala et al, 39 which always contained less than 20% of IFN-γ-producing cells (Supplemental Figure 7) , however, a significant (always >50%) proportion of the IL-17A-captured cells produced IFN-γ (Supplemental Figure 8) , so this approach could not be further pursued due to the impurity of the cells.
In vivo-differentiated
Activation-induced FOXP3 limits the expansion of Th17 cells.
To investigate the function of FOXP3 in Th1 and Th17 cells, chemokine receptor-sorted Th1 and
Th17 cells were transduced with control or siFOXP3 lentivirus and expanded for two weeks. In contrast, the expansion potential of FOXP3-deficient Th1 cells was variable, with no significant difference in proliferation. The difference in expansion potential between Th1 and Th17 cells confirms our previous finding and recent reports.
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Activation-induced FOXP3 limits IFN-γ production by Th17 cells.
We next asked whether cytokine production was altered in siFOXP3-tranduced Th1 and Th17 cells. Because FOXP3 expression remained high in the second week after TCR activation of Th17 cells, we examined cytokine production at this time point. Eight days after activation, cells were washed and re-plated and supernatants were collected after 48h. There was an average of 
Activation-induced FOXP3 up-regulates CCR4 in Th17 cells.
We next examined whether activation-induced FOXP3 positively regulates cell surface markers in Th1 and Th17 cells. CCR4 expression was significantly decreased in siFOXP3-Th17 cells compared to control Th17 cells ( Figure 7A and Supplemental Figure 9) . Similarly, expression of CCR6 expression was reduced in siFOXP3-Th17, but this difference was not statistically significant ( Figure 7B and Supplemental Figure 9 ). In contrast, there was no difference in CTLA-4 expression between siFOXP3-and siLuc-Th17 or Th1 cells (Figures 7C and D) . There was also no difference in CCR4 or CCR6 expression in siFOXP3-transduced Th1 cells since they do not highly express these proteins (data not shown).
Discussion
We investigated the role of activation-induced FOXP3 in human CD4 + T cells and found that this protein acts as an intrinsic negative regulator of T cell proliferation and cytokine production. We examined how FOXP3 affects cytokine production by Tconv cells and found that FOXP3 null T cell clones had significantly increased cytokine production. This phenotype, however, was not as robust in siFOXP3-transduced T conv cells; although there was a trend of increased cytokine production, it was not statistically significant. This difference is likely because the FOXP3 null T cells clones do not express any FOXP3 whereas the knock-down only reduced FOXP3 expression by ~50%. In contrast, in Th17 cells, there is a strong intrinsic role for FOXP3 in regulating activation: a significant increase in IFN-γ production was evident even with only ~65% reduction in FOXP3 expression. These data suggest that FOXP3 may restrain Th17 cells from becoming the IL-17 + IFN-γ + T cells that are implicated in many inflammatory diseases. [34] [35] [36] [37] [38] [39] FOXP3 is known to suppress the Th1 developmental program during Th17 differentiation, 40 and our data suggest that this function continues in fully differentiated Th17 cells.
Whether or not FOXP3-expressing Tconv cells acquire suppressive capacity has been debated. 5, [7] [8] [9] [10] [11] 41 In contrast to unpolarized CD4 + T cells or Th1 cells, our findings suggest that with repeated activation Th17 cells may gain regulatory function. In support of this possibility, after repetitive stimulation, Th17 cell clones acquire an increasingly de-methylated TSDR and regulatory capacity.
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, and there is evidence for suppressive IL-17 + FOXP3 + T cells in the blood of healthy individuals 16, 17 and colitic patients. 15 The origin of IL-17 + FOXP3 + cells was assumed to be the result of FOXP3 + Tregs becoming unstable and acquiring IL-17 production, but our data suggest the opposite may also be happening: Th17 cells may acquire FOXP3. A caveat is that the Th17-enriched cells contained a small proportion of cells that expressed FOXP3 and
Helios, but which were not CD25 high, ex vivo. Since both FOXP3 and Helios can be expressed upon TCR activation 12 , it is possible that these are ex vivo activated Th17 cells rather than classical thymus-derived Tregs. Furthermore, contaminating Tregs would not be expected to preferentially expand, and indeed after expansion none of the FOXP3 + cells were Helios + . Thus, although we cannot exclude the possibility that contaminating Tregs contribute to the reported phenotype of the Th17-enriched cells, collectively the data argue against this possibility. CTLA-4 (n = 2-3)
